GNTA — Genenta Science SpA Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.6 | ||
| Price to Tang. Book | 0.6 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -22.18% | ||
| Return on Equity | -38.03% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | n/a | n/a | n/a | n/a | n/a | n/a | 52 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Genenta Science SpA is an Italy-based company active in the biotechnology, aerospace, defense, and national security sectors. Within its biotechnology activities, the Company's platform Temferon focuses on hematopoietic stem and progenitor cells (HSPCs) engineered to deliver therapeutic genes and modulate immune responses. Regarding the aerospace and defense sector, through Sophia High Tech S.r.l., the Company is involved in the design, engineering, prototyping, and manufacturing of mechanical components for aerospace and defense applications. Through ATC (Armi Tattiche Custom), Genenta Science SpA is engaged in the manufacturing of tactical systems and related components. Its product portfolio includes tactical rifles, chassis systems, optics mounts, bipods, and accessories. Genenta Science SpA's activities also include the acquisition of majority or full ownership interests in privately held companies operating in sectors subject to Italy's national security regulations.
Directors
- Pierluigi Paracchi CEO
- Luigi Naldini CFD
- Richard Slansky CFO (60)
- Stefania Mazzoleni OTH
- Carlo Russo OTH
- Last Annual
- December 31st, 2025
- Last Interim
- December 31st, 2025
- Incorporated
- July 28th, 2014
- Public Since
- December 15th, 2021
- No. of Employees
- 9
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 23,432,183
- Address
- Via Olgettina 58, MILANO, 20121
- Web
- https://www.genenta.com
- Phone
- Auditors
- Dannible & McKee
Latest News for GNTA
Similar to GNTA
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
As of Today at 20:48 UTC, shares in Genenta Science SpA are trading at $0.63. This share price information is delayed by 15 minutes.
Shares in Genenta Science SpA last closed at $0.63 and the price had moved by -80.49% over the past 365 days. In terms of relative price strength the Genenta Science SpA share price has underperformed the S&P500 Index by -82.62% over the past year.
The overall consensus recommendation for Genenta Science SpA is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreGenenta Science SpA does not currently pay a dividend.
Genenta Science SpA does not currently pay a dividend.
Genenta Science SpA does not currently pay a dividend.
To buy shares in Genenta Science SpA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.63, shares in Genenta Science SpA had a market capitalisation of $14.76m.
Here are the trading details for Genenta Science SpA:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: GNTA
Based on an overall assessment of its quality, value and momentum Genenta Science SpA is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Genenta Science SpA is $7.00. That is 1011.02% above the last closing price of $0.63.
Analysts covering Genenta Science SpA currently have a consensus Earnings Per Share (EPS) forecast of -€0.41 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Genenta Science SpA. Over the past six months, its share price has underperformed the S&P500 Index by -16.28%.
As of the last closing price of $0.63, shares in Genenta Science SpA were trading -40.44% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Genenta Science SpA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.63.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Genenta Science SpA's management team is headed by:
- Pierluigi Paracchi - CEO
- Luigi Naldini - CFD
- Richard Slansky - CFO
- Stefania Mazzoleni - OTH
- Carlo Russo - OTH